Advertisement

International Journal of Hematology

, Volume 75, Issue 3, pp 302–304 | Cite as

Reversible Acceleration of Disease Progression Following Cyclosporin A Treatment in a Patient With Myelodysplastic Syndrome

  • Mitsuru Itoh
  • Kazuhiro Yago
  • Hideto Shimada
  • Kaoru Tohyama
Case Report

Abstract

A 38-year-old Japanese man with myelodysplastic syndrome (MDS), whose bone marrow smears demonstrated hypercellularity, was treated with oral cyclosporin A (CsA) therapy. During the course of this therapy, the numbers of peripheral blood and bone marrow blasts increased and the level of serum lactate dehydrogenase increased.After discontinuation of CsA treatment, all of these levels rapidly decreased. We consider that CsA might accelerate disease progression in certain MDS cases.

Key words

Myelodysplastic syndrome Cyclosporin A Disease progression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome.Cancer. 1997;79:1548–1551.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hellstrom-Lindberg E. Treatment of adult myelodysplastic syndromes.Int J Hematol. 1999;70:141–154.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome.Cancer. 1988;62:958–964.CrossRefPubMedGoogle Scholar
  4. 4.
    Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.Br J Haematol. 1998;100:304–309.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes.Br J Haematol. 1982;51:189–199.CrossRefPubMedGoogle Scholar
  6. 6.
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting— Airlie House, Virginia, November 1997.J Clin Oncol. 1999;17:3835–3849.CrossRefPubMedGoogle Scholar
  7. 7.
    Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome.Int J Hematol. 2000;72:131–133.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Motoji T, Teramura M, Takahashi M, et al. Successful treatment of refractory anemia with high-dose methylprednisolone.Am J Hematol. 1990;33:8–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome.Br J Haematol. 1997;99:699–705.CrossRefPubMedGoogle Scholar
  10. 10.
    Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies.Haematologica. 2000;85:133–138.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Litzow MR, Kyle RA. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome.Am J Hematol. 1989;32:226–229.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Mitsuru Itoh
    • 1
  • Kazuhiro Yago
    • 1
  • Hideto Shimada
    • 1
  • Kaoru Tohyama
    • 2
  1. 1.Division of Hematology and Oncology, Department of Internal MedicineShizuoka General HospitalShizuoka
  2. 2.Department of Laboratory MedicineKyoto UniversityKyotoJapan

Personalised recommendations